Wordt geladen...
Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma
Proteasome inhibition forms the cornerstone of antimyeloma therapy. The first-in-class proteasome inhibitor, bortezomib, either alone or in combination with other chemotherapeutic agents, induces high overall response rates and response qualities in patients with clinically and molecularly defined h...
Bewaard in:
| Hoofdauteurs: | , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Dove Medical Press
2011
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3102580/ https://ncbi.nlm.nih.gov/pubmed/21654882 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CE.S13838 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|